
Results from the SISR trial, a multi-center, randomized study of the CYPHER. Sirolimus-eluting Coronary Stent versus radiation from within a vessel (brachytherapy) in patients with bare-metal in-stent reblockage (restenosis), were presented today at the TCT 2005 Scientific Symposium. The study showed that patients who received the CYPHER. Stent had a significantly lower incidence of target vessel failure at nine months post-procedure compared with patients who received brachytherapy. The SISR trial was sponsored by Cordis Corporation.

